secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001104659-26-058234
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M
-----------------------------------------------------------------------

- YUTREPIA net product sales $129.9M in Q1 2026; over 4,500 prescriptions, ~3,750 patients treated since June 2025 launch.
- Net income $52.9M ($0.60 basic, $0.52 diluted) vs net loss $38.4M ($0.45 loss) in Q1 2025 – third consecutive profitable quarter.
- Adjusted EBITDA $71.2M; cash & equivalents $222.8M, up $32.1M from Q4 2025.
- R&D expenses $12.6M (+$5.6M YoY) driven by L606 and YUTREPIA clinical programs.
- Screening PH-ILD patients for Phase 4 Tyvaso transition study and pivotal Phase 3 Re-Spire study of L606.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926058234/0001104659-26-058234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926058234/tm2614109d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-058234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer